HRP20160513T1 - Agensi koji vrše reverziju antikoagulanta - Google Patents

Agensi koji vrše reverziju antikoagulanta

Info

Publication number
HRP20160513T1
HRP20160513T1 HRP20160513TT HRP20160513T HRP20160513T1 HR P20160513 T1 HRP20160513 T1 HR P20160513T1 HR P20160513T T HRP20160513T T HR P20160513TT HR P20160513 T HRP20160513 T HR P20160513T HR P20160513 T1 HRP20160513 T1 HR P20160513T1
Authority
HR
Croatia
Prior art keywords
reversal agents
anticoagulant reversal
anticoagulant
agents
reversal
Prior art date
Application number
HRP20160513TT
Other languages
English (en)
Croatian (hr)
Inventor
Solomon S. Steiner
Bryan E. Laulicht
Sasha H. Bakhru
Edith Mathiowitz
Original Assignee
Perosphere, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47430065&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20160513(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Perosphere, Inc. filed Critical Perosphere, Inc.
Publication of HRP20160513T1 publication Critical patent/HRP20160513T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20160513TT 2011-11-29 2012-11-29 Agensi koji vrše reverziju antikoagulanta HRP20160513T1 (hr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161564559P 2011-11-29 2011-11-29
US201261614292P 2012-03-22 2012-03-22
US201261641698P 2012-05-02 2012-05-02
US201261666291P 2012-06-29 2012-06-29
PCT/US2012/066938 WO2013082210A1 (en) 2011-11-29 2012-11-29 Anticoagulant reversal agents
EP12806229.6A EP2785700B1 (en) 2011-11-29 2012-11-29 Anticoagulant reversal agents

Publications (1)

Publication Number Publication Date
HRP20160513T1 true HRP20160513T1 (hr) 2016-07-15

Family

ID=47430065

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20160513TT HRP20160513T1 (hr) 2011-11-29 2012-11-29 Agensi koji vrše reverziju antikoagulanta

Country Status (34)

Country Link
US (5) US9522892B2 (enExample)
EP (1) EP2785700B1 (enExample)
JP (1) JP6134731B2 (enExample)
KR (1) KR101892330B1 (enExample)
CN (1) CN104080772B (enExample)
AP (1) AP2014007662A0 (enExample)
AR (1) AR089020A1 (enExample)
AU (1) AU2012345975B2 (enExample)
BR (1) BR112014012892B1 (enExample)
CA (1) CA2856540C (enExample)
CL (1) CL2014001399A1 (enExample)
CO (1) CO6990738A2 (enExample)
CR (1) CR20140310A (enExample)
CY (1) CY1117414T1 (enExample)
DK (1) DK2785700T3 (enExample)
EA (1) EA027603B1 (enExample)
EC (1) ECSP14006696A (enExample)
ES (1) ES2569674T3 (enExample)
HR (1) HRP20160513T1 (enExample)
HU (1) HUE027452T2 (enExample)
IL (1) IL232788B (enExample)
ME (1) ME02424B (enExample)
MX (1) MX349514B (enExample)
PE (1) PE20141295A1 (enExample)
PH (1) PH12014501176B1 (enExample)
PL (1) PL2785700T3 (enExample)
PT (1) PT2785700E (enExample)
RS (1) RS54738B1 (enExample)
SG (1) SG11201402713WA (enExample)
SI (1) SI2785700T1 (enExample)
SM (1) SMT201600161B (enExample)
UA (1) UA116336C2 (enExample)
WO (1) WO2013082210A1 (enExample)
ZA (1) ZA201404793B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9999690B2 (en) 2013-11-08 2018-06-19 Perosphere Pharmaceuticals Inc. Labeled compounds and methods of imaging, diagnosing cartilage disorders and diseases, and monitoring cartilage health using labeled and unlabeled compounds
JP7034084B2 (ja) 2016-03-28 2022-03-11 インサイト・コーポレイション Tam阻害剤としてのピロロトリアジン化合物
CA3077308A1 (en) 2017-09-27 2019-04-04 Incyte Corporation Salts of pyrrolotriazine derivatives useful as tam inhibitors
BR112019027735A8 (pt) * 2017-11-13 2020-10-13 Maximum Fidelity Surgical Simulations Llc reconstituição de circulação pós-morte, métodos e procedimentos especializados
EA202190153A1 (ru) 2018-06-29 2021-04-09 Инсайт Корпорейшн Составы ингибитора axl/mer
US11716989B2 (en) 2019-04-16 2023-08-08 Maximum Fidelity Surgical Simulations, LLC Cadaver preservation systems and methods
US11915610B2 (en) 2019-05-15 2024-02-27 Maximum Fidelity Surgical Simulations, LLC Cadaverous heart model
CN112010930B (zh) * 2019-05-28 2022-08-02 首都医科大学 Rgd修饰的五环哌嗪二酮及其制备和应用
AU2021230385A1 (en) 2020-03-06 2022-09-22 Incyte Corporation Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
WO2024199096A1 (zh) * 2023-03-24 2024-10-03 陕西麦科奥特科技有限公司 一种抗凝逆转剂及其制备方法和应用
CN117624137A (zh) * 2023-12-04 2024-03-01 中国药科大学 三嗪骨架小分子肝素逆转剂及其制备方法与用途
EP4667582A1 (en) * 2024-06-20 2025-12-24 Instrumentation Laboratory Company Factor xa reagent

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3678157A (en) * 1968-10-23 1972-07-18 Oreal Hair treatment compositions containing polycondensable compounds
IL115420A0 (en) * 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
US6069232A (en) * 1995-10-02 2000-05-30 Hoechst Marion Roussel, Inc. Polyfluoroalkyl tryptophan tripeptide thrombin inhibitors
US6080852A (en) 1996-06-27 2000-06-27 The Perkin-Elmer Corporation 4,7-dichlororhodamine dyes
EP0932615A1 (en) 1996-10-11 1999-08-04 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
CA2285454A1 (en) * 1997-04-07 1998-10-15 Axys Pharmaceuticals Corporation Compounds and compositions for treating diseases associated with serine protease, particularly tryptase, activity
FR2781221B1 (fr) * 1998-07-17 2000-10-13 Lafon Labor Piperazinones substituees en alpha
CA2320730A1 (en) * 1998-12-23 2000-07-06 Renhua Li Thrombin or factor xa inhibitors
CA2373610A1 (en) 1999-05-19 2000-11-23 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
EP1377554A1 (en) * 1999-06-16 2004-01-07 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
EP1274676A2 (en) 2000-04-17 2003-01-15 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
EP1294684A2 (en) * 2000-06-29 2003-03-26 Bristol-Myers Squibb Pharma Company THROMBIN OR FACTOR Xa INHIBITORS
CA2462305A1 (en) 2001-10-03 2003-04-10 Michael S. South 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
WO2003082809A1 (en) * 2002-03-27 2003-10-09 Glaxo Group Limited Diaminoacid-aminoacid-polyamine based gemini surfactant compounds
JPWO2003099324A1 (ja) * 2002-05-23 2005-09-22 中外製薬株式会社 組織因子阻害剤中和剤及び活性型血液凝固第vii因子製剤中和剤
GB0214122D0 (en) * 2002-06-19 2002-07-31 Eastman Kodak Co High contrast photographic element containing a polyhydrazide nucleating agent
SE0400014D0 (sv) * 2004-01-08 2004-01-08 Astrazeneca Ab Heterocyclic derivatives
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
KR102069498B1 (ko) * 2007-09-28 2020-01-23 포톨라 파마슈티컬스, 인코포레이티드 인자 Xa 저해제에 대한 안티도트 및 그것을 사용하는 방법
GB2476643B (en) 2009-12-23 2012-11-14 Haomamedica Ltd 1,4-Dihydro-1,4-dioxonaphtalene derivatives as anticoagulants
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
AP2013007046A0 (en) 2011-03-30 2013-08-31 Boehringer Ingelheim Int Anticoagulant antidotes

Also Published As

Publication number Publication date
US9522892B2 (en) 2016-12-20
ME02424B (me) 2016-09-20
CO6990738A2 (es) 2014-07-10
US20130137702A1 (en) 2013-05-30
SI2785700T1 (sl) 2016-09-30
JP6134731B2 (ja) 2017-05-24
PL2785700T3 (pl) 2016-09-30
MX349514B (es) 2017-08-02
US20210169874A1 (en) 2021-06-10
CA2856540A1 (en) 2013-06-06
EP2785700A1 (en) 2014-10-08
ES2569674T3 (es) 2016-05-12
US20170056396A1 (en) 2017-03-02
CY1117414T1 (el) 2017-04-26
BR112014012892A8 (pt) 2021-06-08
DK2785700T3 (en) 2016-06-13
CA2856540C (en) 2018-04-03
AP2014007662A0 (en) 2014-05-31
SMT201600161B (it) 2016-07-01
BR112014012892A2 (pt) 2017-06-13
HUE027452T2 (en) 2016-09-28
JP2014534270A (ja) 2014-12-18
SG11201402713WA (en) 2014-06-27
EP2785700B1 (en) 2016-03-09
ECSP14006696A (es) 2015-06-30
BR112014012892B1 (pt) 2022-12-20
PT2785700E (pt) 2016-06-02
IL232788B (en) 2018-05-31
NZ625337A (en) 2016-11-25
CL2014001399A1 (es) 2014-11-03
MX2014006349A (es) 2014-09-04
AU2012345975B2 (en) 2016-12-15
CN104080772B (zh) 2016-10-05
US20240366592A1 (en) 2024-11-07
KR101892330B1 (ko) 2018-08-27
HK1202858A1 (en) 2015-10-09
US9877961B2 (en) 2018-01-30
AR089020A1 (es) 2014-07-23
IL232788A0 (en) 2014-08-03
ZA201404793B (en) 2015-04-29
CR20140310A (es) 2014-08-20
AU2012345975A1 (en) 2014-05-29
CN104080772A (zh) 2014-10-01
KR20140107259A (ko) 2014-09-04
WO2013082210A1 (en) 2013-06-06
UA116336C2 (uk) 2018-03-12
US20180207152A1 (en) 2018-07-26
PH12014501176A1 (en) 2014-09-01
PE20141295A1 (es) 2014-10-01
EA201490823A1 (ru) 2015-01-30
RS54738B1 (sr) 2016-10-31
EA027603B1 (ru) 2017-08-31
PH12014501176B1 (en) 2014-09-01

Similar Documents

Publication Publication Date Title
ZA201404793B (en) Anticoagulant reversal agents
ZA201403090B (en) Tropicalizing agent
PL3701800T3 (pl) Zastosowanie
CO6970601A2 (es) Nueva combinación
GB201111742D0 (en) Solution
GB2494857B (en) Cuvette
IL227377A0 (en) Combinations
TWI562734B (en) Sense-improving agent
EP2764870A4 (en) MEANS FOR IMPROVED SENSUAL ASSESSMENT
GB201402900D0 (en) Antifoam agents
GB2496392B (en) Construction kit
FI10522U1 (fi) Sihti
GB201122518D0 (en) Roberts microworld
DE112012001786A5 (de) Reinigungsset
GB201102289D0 (en) New use
ZA201403872B (en) New combination
GB201119436D0 (en) Use
GB201102292D0 (en) New use
ES1076331Y (es) Trocola pesadora
GB201103956D0 (en) Aspirator
GB201103770D0 (en) Novel use
GB201108947D0 (en) Novel use
GB201108061D0 (en) Pump out
AU335234S (en) Sunglasses
AU335228S (en) Sunglasses